Crescendo Biologics to present at the 2024 AACR Annual Meeting

06 Mar 2024
www.globenewswire.com
License out/inPhase 1ImmunotherapyAACRCell Therapy
Crescendo Biologics to present at the 2024 AACR Annual Meeting
Crescendo Biologics to present at the 2024 AACR Annual Meeting
Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
Details of the abstracts:
Archer, S et al, CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumors, Poster Section 3, Abstract #5313
Pierce, AJ et al, CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumors, Poster Section 3, Abstract #5302
Both posters will be presented in the Immune Modulation Employing Agonist or Co-Stimulatory Approaches Session, on Tuesday 9 April 2024, 1:30 pm - 5:00 pm PST, and will be made available on the Publications section of the company’s website following their presentation at the meeting.
-Ends-
For more information, please contact:
Crescendo BiologicsICR Consilium Theodora Harold, CEO
+ 44 (0) 12 2349 7140
investors@crescendobiologics.com
media@crescendobiologics.comMary-Jane Elliott, David Daley, Sukaina Virji
crescendo@consilium-comms.com
About CB307
CB307 is Crescendo’s lead clinical candidate, a first-in-class, half-life extended, CD137 x PSMA bispecific Humabody®, designed to deliver a safer and more durable anti-cancer T cell response.
CB307 conditionally activates only tumour-specific T cells, exclusively within the tumour microenvironment using the CD137 co-stimulatory mechanism. Its unique format enables potent, tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA+ cancerPSMA+ cancer indications to address a large unmet medical need.
Clinical development of CB307 is on track with the Phase 1b POTENTIA trial ongoing in adult patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC)PSMA+ metastatic castration-resistant prostate cancer (mCRPC). POTENTIA (NCT04839991) is an open-label, dose escalation and cohort expansion study to assess the safety, tolerability and preliminary efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted T cell-enhancing therapeutics derived from its proprietary Humabody® VH platform. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with Takeda and BioNTech, and an exclusive worldwide licensing agreement with Zai Lab. Located in Cambridge, UK, Crescendo is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital and Kreos Capital. Visit www.crescendobiologics.com and follow on LinkedIn and X (Twitter).


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.